Gainers

• LogicMark (NASDAQ:LGMK) stock increased by 34.7% to $0.19 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.5 million. The company's, Q4 earnings came out yesterday.
• Arcturus Therapeutics (NASDAQ:ARCT) stock rose 28.89% to $19.98. The company's market cap stands at $530.5 million. As per the news, the Q4 earnings report came out yesterday.
• Biocept (NASDAQ:BIOC) stock moved upwards by 16.12% to $0.36. The company's market cap stands at $6.1 million.
• Emergent BioSolutions (NYSE:EBS) stock rose 14.94% to $10.23. The company's market cap stands at $512.9 million.
• Meihua Intl Medical Techs (NASDAQ:MHUA) shares moved upwards by 14.88% to $7.72. The company's market cap stands at $184.8 million.
• Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 14.63% to $1.41. The company's market cap stands at $19.2 million.

Losers

• Pieris Pharmaceuticals (NASDAQ:PIRS) stock declined by 23.0% to $1.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $84.8 million. The company's, Q4 earnings came out today.
• SomaLogic (NASDAQ:SLGC) shares declined by 14.53% to $2.0. The market value of their outstanding shares is at $375.0 million. As per the press release, Q4 earnings came out yesterday.
• bluebird bio (NASDAQ:BLUE) stock decreased by 11.58% to $3.82. The market value of their outstanding shares is at $393.1 million. The company's, Q4 earnings came out today.
• Sharecare (NASDAQ:SHCR) shares fell 10.8% to $1.9. The company's market cap stands at $671.6 million. As per the press release, Q4 earnings came out today.
• Reshape Lifesciences (NASDAQ:RSLS) stock declined by 9.62% to $2.82. The market value of their outstanding shares is at $5.0 million. As per the press release, Q4 earnings came out today.
• Biolase (NASDAQ:BIOL) shares decreased by 8.24% to $0.36. The market value of their outstanding shares is at $8.7 million. The company's, Q4 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.